Biomaterial Constraints Could Limit Progress of 3D Printing
For 3D printing to thrive in the medical device space, the use of biomaterials must be expanded.
Tag Archives: innovation
Regulatory Innovation Should Adapt to New Health Economy
Forty-three percent of pharma and life sciences executives now support FDA evaluating drugs and devices based on both clinical and economic effectiveness.
Forty-three percent of pharma and life sciences executives now support FDA evaluating drugs and devices based on both clinical and economic effectiveness.
“Med-tech Innovation Happening at Speed of Technology, not Healthcare”
In this interview Brian Williams, Director, Healthcare Strategy and Innovation at PwC, talks about the impact of med-tech trends such as outcomes based reimbursement, lessons learned in emerging markets, and impact of the device tax.
In this interview Brian Williams, Director, Healthcare Strategy and Innovation at PwC, talks about the impact of med-tech trends such as outcomes based reimbursement, lessons learned in emerging markets, and impact of the device tax.
The Changing Healthcare Ecosystem and a “Systems Thinking” Approach
Systems thinking is a disciplined way of thinking beyond the traditional boundaries of a product, and considers the complete flow of information or activities across a cooperating set of systems and human interventions to complete an intended job. For healthcare, this includes the span of activities for people, devices, information systems, and processes needed to meet various clinical and home healthcare scenarios.
Systems thinking is a disciplined way of thinking beyond the traditional boundaries of a product, and considers the complete flow of information or activities across a cooperating set of systems and human interventions to complete an intended job. For healthcare, this includes the span of activities for people, devices, information systems, and processes needed to meet various clinical and home healthcare scenarios.
Making Translational Engineering Work: A Conversation with MIT’s Robert Langer
For the past decade “translational science” and “translational medicine” have been cherished buzzwords, raising the prospect of faster, better, more seamless transfer of discoveries from bench to bedside. Too often, though, it doesn’t work. Differences in the cultures of academia and medical manufacturing, and a poor grasp of regulatory and reimbursement issues, or of what makes a bright idea into a clinically useful, commercially viable product have scuttled more than one promising innovation.
